Suzhou Novoprotein (China) Performance
| 688137 Stock | 37.00 0.23 0.63% |
On a scale of 0 to 100, Suzhou Novoprotein holds a performance score of 10. The entity has a beta of 0.0807, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Suzhou Novoprotein's returns are expected to increase less than the market. However, during the bear market, the loss of holding Suzhou Novoprotein is expected to be smaller as well. Please check Suzhou Novoprotein's sortino ratio, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to make a quick decision on whether Suzhou Novoprotein's existing price patterns will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Suzhou Novoprotein Scientific are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Suzhou Novoprotein sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Forward Dividend Yield 0.0135 | Forward Dividend Rate 0.5 | Ex Dividend Date 2024-08-01 |
| Begin Period Cash Flow | 929.3 M |
Suzhou |
Suzhou Novoprotein Relative Risk vs. Return Landscape
If you would invest 2,996 in Suzhou Novoprotein Scientific on September 5, 2024 and sell it today you would earn a total of 704.00 from holding Suzhou Novoprotein Scientific or generate 23.5% return on investment over 90 days. Suzhou Novoprotein Scientific is generating 0.4125% of daily returns and assumes 3.1281% volatility on return distribution over the 90 days horizon. Simply put, 27% of stocks are less volatile than Suzhou, and 92% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Suzhou Novoprotein Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Suzhou Novoprotein's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Suzhou Novoprotein Scientific, and traders can use it to determine the average amount a Suzhou Novoprotein's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1319
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 688137 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.13 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.41 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Suzhou Novoprotein is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Suzhou Novoprotein by adding it to a well-diversified portfolio.
Suzhou Novoprotein Fundamentals Growth
Suzhou Stock prices reflect investors' perceptions of the future prospects and financial health of Suzhou Novoprotein, and Suzhou Novoprotein fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Suzhou Stock performance.
| Return On Equity | -0.0099 | ||||
| Return On Asset | -0.0228 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | 0.58 % | ||||
| Current Valuation | 1.98 B | ||||
| Shares Outstanding | 70.18 M | ||||
| Price To Book | 1.22 X | ||||
| Price To Sales | 18.88 X | ||||
| Revenue | 153.19 M | ||||
| Gross Profit | 228.37 M | ||||
| EBITDA | (71.71 M) | ||||
| Net Income | 12.84 M | ||||
| Total Debt | 11.08 M | ||||
| Book Value Per Share | 29.05 X | ||||
| Cash Flow From Operations | 69.16 M | ||||
| Earnings Per Share | (0.31) X | ||||
| Total Asset | 2.3 B | ||||
| Retained Earnings | 149.52 M | ||||
About Suzhou Novoprotein Performance
By analyzing Suzhou Novoprotein's fundamental ratios, stakeholders can gain valuable insights into Suzhou Novoprotein's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Suzhou Novoprotein has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Suzhou Novoprotein has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Suzhou Novoprotein is entity of China. It is traded as Stock on SHG exchange.Things to note about Suzhou Novoprotein performance evaluation
Checking the ongoing alerts about Suzhou Novoprotein for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Suzhou Novoprotein help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Suzhou Novoprotein had very high historical volatility over the last 90 days | |
| Suzhou Novoprotein has high likelihood to experience some financial distress in the next 2 years | |
| About 73.0% of the company shares are owned by insiders or employees |
- Analyzing Suzhou Novoprotein's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Suzhou Novoprotein's stock is overvalued or undervalued compared to its peers.
- Examining Suzhou Novoprotein's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Suzhou Novoprotein's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Suzhou Novoprotein's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Suzhou Novoprotein's stock. These opinions can provide insight into Suzhou Novoprotein's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Suzhou Stock analysis
When running Suzhou Novoprotein's price analysis, check to measure Suzhou Novoprotein's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Suzhou Novoprotein is operating at the current time. Most of Suzhou Novoprotein's value examination focuses on studying past and present price action to predict the probability of Suzhou Novoprotein's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Suzhou Novoprotein's price. Additionally, you may evaluate how the addition of Suzhou Novoprotein to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |